ERBB2 and breast disorder: Increased expression of STAT3, which may alter cellular proliferation, angiogenesis, and apoptosis, can be activated by HER2 [32,33], and has been associated with advanced disease and poor response to chemotherapy [34], thus genomic amplification of 17q12-q21 may increase STAT3 levels and contribute to aggressive, refractory breast disease.